Scientific Officer / Higher Scientific Officer in Myeloma Model Development and Target Validation
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit, within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 170 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible. Our biologists work alongside world-class chemists and drug metabolism specialists focusing on new molecular targets emerging from human genome and ground breaking cell biology research. This is an exciting and fast moving area of cancer research, and offers the opportunity to work within a multi-disciplinary environment using state-of-the-art techniques and equipment.
A position is available for a Scientific Officer / Higher Scientific Officer to use advanced cellular biology techniques together with contemporary biochemical approaches to validate novel myeloma therapeutics using cell line and patient derived myeloma models. This position is critical for strengthening the Cancer Therapeutics Unit drug discovery portfolio.
Salary will be within the range from £25,911 - £36,001 per annum inclusive based on qualifications and previous experience.
The appointment will be for 1 year fixed contract with possibility to extend depending on further funding.
This Program is closed to applications.